Bain Capital Life Sciences Investors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250,000	Closed	-$2.49M	–	35
2021 Q3	$2.49M	Hold	250,000	–	–	0.15%	33
2021 Q2	$2.59M	Hold	250,000	–	–	0.17%	30
2021 Q1	$2.55M	Hold	250,000	–	–	0.14%	31
2020 Q4	$2.84M	Buy	+250,000	New	+$2.65M	0.18%	26

Other funds holding MLTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bain Capital Life Sciences Investors's MLTX Position: Q4 2021 in Review

Bain Capital Life Sciences Investors sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2021, closing a stake of 250,000 shares — an estimated $2.49M sold.

Bain Capital Life Sciences Investors first reported a position in MLTX in Q4 2020 and held it in 4 quarters. The position peaked at $2.84M in Q4 2020. 45 funds tracked by Wall St. Rank hold MLTX as of Q4 2021.

Bain Capital Life Sciences Investors reported no remaining MoonLake Immunotherapeutics position as of Q4 2021 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 250,000 MoonLake Immunotherapeutics shares in Q4 2021, an estimated $2.49M.
Bain Capital Life Sciences Investors first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 4 quarters.
Bain Capital Life Sciences Investors's MoonLake Immunotherapeutics position peaked at $2.84M in Q4 2020.
45 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2021.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2021, filed 14 Feb 2022.